Interleukin-2-inducible T cell kinase (ITK) as a Therapeutic Target for Cancer Treatment

Technology #12-0029

ITK may be a novel target for melanoma or other cancers. The IL-2 inducible T-cell kinase (ITK) promoter is demethylated in melanomas but not in benign moles or normal skin melanocytes. Studies evaluating melanoma lines, primary cells and mouse xenograft models indicate that melanoma tumors are susceptible to treatment with ITK inhibitors.

Advantages:

• May represent a new target for melanoma and other malignancies
• ITK inhibitors are in development for cancer, autoimmunity, and inflammatory diseases

Inventors

Nancy Thomas
For additional information, contact

Kyle Bartholomew
Commercialization Manager
kyle.bartholomew@unc.edu
919.962.5921